There are 2949 resources available
998P - The biomarkers associated with hyperprogression (HP) to immune checkpoint inhibitors (ICIs) in Chinese hepatocellular carcinoma (HCC) patients
Presenter: Cheng Wei
Session: E-Poster Display
Resources:
Abstract
999P - Real-life clinical data of cabozantinib for unresectable hepatocellular carcinoma
Presenter: Francesco Tovoli
Session: E-Poster Display
Resources:
Abstract
1000P - Trends of characteristics, treatment and prognosis of hepatocellular carcinoma in Japan during the last decade
Presenter: Masayuki Ueno
Session: E-Poster Display
Resources:
Abstract
1001P - PD1midKLRG1+Tbethigh effector memory T in the peripheral blood correlates with tumor response to combined therapy with lenvatinib and anti-PD-1 antibodies in unresectable hepatocellular carcinoma
Presenter: Huichuan Sun
Session: E-Poster Display
Resources:
Abstract
1002P - Usefulness of hand-foot skin reaction as a prognostic marker in patients with hepatocellular carcinoma treated with sorafenib: Close cooperation between pharmacists and oncologist changes prognosis
Presenter: Toshiro Kamoshida
Session: E-Poster Display
Resources:
Abstract
1003P - Baseline (BL) liver function and outcomes in patients (pts) with unresectable hepatocellular carcinoma (HCC) in KEYNOTE-240
Presenter: Arndt Vogel
Session: E-Poster Display
Resources:
Abstract
1004P - Modified albumin-bilirubin-TNM score better predictor of survival in patients with hepatocellular carcinoma
Presenter: Myriam Ayari
Session: E-Poster Display
Resources:
Abstract
1005P - Response rate to immune-checkpoint inhibitors in patients with advanced hepatocellular carcinoma: A systematic review with quantitative data analysis
Presenter: Dmitrii Shek
Session: E-Poster Display
Resources:
Abstract
1006P - PD-L1, tumor mutational burden, and overall survival among patients undergoing surgical treatment for hepatocellular carcinoma prior to systemic therapy
Presenter: Torben Steiniche
Session: E-Poster Display
Resources:
Abstract
1007P - cfDNA and ctDNA variations are predictive of disease progression to conventional transarterial chemoembolization (cTACE) in patients with hepatocellular carcinoma (HCC)
Presenter: David Sefrioui
Session: E-Poster Display
Resources:
Abstract